Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 13, Pages 3078
Publisher
MDPI AG
Online
2022-06-24
DOI
10.3390/cancers14133078
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.
- (2022) Masahito Kotaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
- (2022) Jeanne Tie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.
- (2021) Tenna V Henriksen et al. JOURNAL OF CLINICAL ONCOLOGY
- ctDNA and Adjuvant Therapy for Colorectal Cancer: Time to Re-Invent Our Treatment Paradigm
- (2021) Mahendra Naidoo et al. Cancers
- Minimal Residual Disease, Metastasis and Immunity
- (2021) Jordi Badia-Ramentol et al. Biomolecules
- Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer
- (2021) Erik Osterman et al. ACTA ONCOLOGICA
- Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients
- (2021) Aparna R. Parikh et al. CLINICAL CANCER RESEARCH
- Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
- (2021) Jeanne Tie et al. PLOS MEDICINE
- Estimated Projection of US Cancer Incidence and Death to 2040
- (2021) Lola Rahib et al. JAMA Network Open
- Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial
- (2021) Julien Taieb et al. CLINICAL CANCER RESEARCH
- Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
- (2021) Tenna Vesterman Henriksen et al. CLINICAL CANCER RESEARCH
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Latency and interval therapy affect the evolution in metastatic colorectal cancer
- (2020) Hamid Nikbakht et al. Scientific Reports
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- Preanalytical variables that affect the outcome of cell-free DNA measurements
- (2020) Vida Ungerer et al. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES
- The effect of surgical trauma on circulating free DNA levels in cancer patients – implications for studies of circulating tumor DNA
- (2020) Tenna V. Henriksen et al. Molecular Oncology
- Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
- (2020) M.C. Liu et al. ANNALS OF ONCOLOGY
- Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
- (2020) G. Argiles et al. ANNALS OF ONCOLOGY
- Challenges and opportunities of cfDNA analysis implementation in clinical practice: Perspective of the International Society of Liquid Biopsy (ISLB)
- (2020) Christian Rolfo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- (2020) Arvind Dasari et al. Nature Reviews Clinical Oncology
- Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions
- (2020) Sakti Chakrabarti et al. World Journal of Gastrointestinal Oncology
- Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
- (2020) Laura Keller et al. BRITISH JOURNAL OF CANCER
- Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence
- (2020) Hao Xie et al. CLINICAL CANCER RESEARCH
- Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies
- (2020) Jeanne Tie et al. INTERNATIONAL JOURNAL OF CANCER
- Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
- (2020) Yi-Long Wu et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
- (2020) Sakti Chakrabarti et al. Cancers
- Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer
- (2020) Noelia Tarazona et al. ESMO Open
- International liquid biopsy standardization alliance white paper
- (2020) Dana Connors et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pattern, Stage, and Time of Recurrent Colorectal Cancer After Curative Surgery
- (2019) Salman Yousuf Guraya Clinical Colorectal Cancer
- Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses
- (2019) C Abbosh et al. ANNALS OF ONCOLOGY
- Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
- (2019) Yuxuan Wang et al. JAMA Oncology
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- (2019) Thomas Reinert et al. JAMA Oncology
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
- (2019) N Tarazona et al. ANNALS OF ONCOLOGY
- Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
- (2019) Jeanne Tie et al. JAMA Oncology
- Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction
- (2019) Jee-Soo Lee et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study
- (2018) Jeanne Tie et al. GUT
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recurrence and Cancer-Specific Death After Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) P H Chapuis et al. Colorectal Disease
- Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology
- (2018) Erik Osterman et al. DISEASES OF THE COLON & RECTUM
- Enhanced detection of circulating tumor DNA by fragment size analysis
- (2018) Florent Mouliere et al. Science Translational Medicine
- Cancer stem cells revisited
- (2017) Eduard Batlle et al. NATURE MEDICINE
- False-Positive Elevations of Carcinoembryonic Antigen in Patients With a History of Resected Colorectal Cancer
- (2017) Anya Litvak et al. Journal of the National Comprehensive Cancer Network
- Improved survival of colorectal cancer in Denmark during 2001–2012 – The efforts of several national initiatives
- (2016) Lene H. Iversen et al. ACTA ONCOLOGICA
- Long-term results following an anatomically based surgical technique for resection of colon cancer: a comparison with results from complete mesocolic excision
- (2016) L. Bokey et al. Colorectal Disease
- Global patterns and trends in colorectal cancer incidence and mortality
- (2016) Melina Arnold et al. GUT
- Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group
- (2016) Rob Pieters et al. JOURNAL OF CLINICAL ONCOLOGY
- Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?
- (2016) Lars A. Påhlman et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
- (2016) Jeanne Tie et al. Science Translational Medicine
- Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
- (2015) J. Tie et al. ANNALS OF ONCOLOGY
- Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer: The FFCD PRODIGE 13 randomised phase III trial
- (2015) Côme Lepage et al. DIGESTIVE AND LIVER DISEASE
- Minimal residual disease in cancer therapy – Small things make all the difference
- (2015) Sohvi Blatter et al. DRUG RESISTANCE UPDATES
- Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery
- (2015) Thomas Reinert et al. GUT
- Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial
- (2015) Hans-Joachim Schmoll et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According toBRAFMutation and Mismatch Repair Status of the MOSAIC Study
- (2015) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Preventing clonal evolutionary processes in cancer: Insights from mathematical models
- (2015) Ignacio A. Rodriguez-Brenes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature
- (2014) Camilla Böckelman et al. ACTA ONCOLOGICA
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors
- (2012) John M. Kirkwood et al. CANCER TREATMENT REVIEWS
- The relation between lymph node status and survival in Stage I-III colon cancer: results from a prospective nationwide cohort study
- (2012) J. Lykke et al. Colorectal Disease
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Richard A Adams et al. LANCET ONCOLOGY
- Evidence for Cure by Adjuvant Therapy in Colon Cancer: Observations Based on Individual Patient Data From 20,898 Patients on 18 Randomized Trials
- (2009) Daniel Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
- (2009) Thierry André et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More